Table 1.

CTC counts before initiating treatment and association with clinical and blood collection characteristics

CharacteristicPoints with CTC dataP value Mann–Whitney
Age, y
 <6524
 ≥6513
P0.0556
Race
 Caucasian33
 Asian4
P0.5572
Histology
 Adenocarcinoma24
 Squamous9
P0.9837
Gender
 Male21
 Female160.8042
Smoking
 Yes31
 No6
P0.8026
Genotype
 EGFR mut8
 EGFR WT21
 KRAS mut7
 KRAS WT24
 EGFR WT, KRAS WT14
P value EGFR mut vs. WT0.0941
P value KRAS mut vs. WT0.1808
P value EGFR mut vs. WT for KRAS and EGFR0.0621
P value KRAS mut vs. WT for KRAS and EGFR0.0648
Tumor burden
 Sld at baseline (below median)18
 Sld at baseline (above median)19
P0.747
RECIST response
 Partial response7
 Stable disease or progressive disease12
P0.0091
ECOG
 09
 121
 27
P0.4813
Blood shipment site
 Australia21
 US16
P0.6309
Blood shipment time
 ≤3 d28
 >3 d6
P0.3682

NOTE: P value is based on 2-tailed Mann–Whitney U test except for ECOG score which used a Kruskal–Wallis test for 3-way comparison.

Abbreviation: Sld, sum of the longest unidimensional diameter.